Comparison of safety and immunogenicity in the elderly after receiving either Comirnaty or Spikevax monovalent XBB1.5 COVID-19 vaccine. Mok CKP, Tang YS, Tan CW, Chong KC, et al. J Infect 2024;90:106374.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Mok CKP, Tang YS, Tan CW, Chong KC, et al. Comparison of safety and immunogenicity in the elderly after receiving either Comirnaty or Spikevax monovalent XBB1.5 COVID-19 vaccine. J Infect 2024;90:106374.
PMID: 39657850